메뉴 건너뛰기




Volumn 42, Issue 3, 2012, Pages 637-646

Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer

Author keywords

Anaplastic thyroid cancer; Aurora kinase inhibitors; Mitotic arrest; Proteasome inhibitors; Xenotransplantation

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; AURORA KINASE; BORTEZOMIB; CASPASE 3; PROTEASOME; PROTEIN SERINE THREONINE KINASE; UBIQUITIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BENZAZEPINE DERIVATIVE; BORONIC ACID DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ENZYME INHIBITOR; PYRAZINE DERIVATIVE; VASCULOTROPIN A;

EID: 84878257523     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9665-4     Document Type: Article
Times cited : (13)

References (44)
  • 1
    • 34248203755 scopus 로고    scopus 로고
    • Surgical options in undifferentiated thyroid carcinoma
    • 17483987 10.1007/s00268-007-0776-7
    • B.H. Lang, C.Y. Lo, Surgical options in undifferentiated thyroid carcinoma. World J. Surg. 31(5), 969-977 (2007)
    • (2007) World J. Surg. , vol.31 , Issue.5 , pp. 969-977
    • Lang, B.H.1    Lo, C.Y.2
  • 2
    • 79953237137 scopus 로고    scopus 로고
    • Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006
    • 21186939 10.1089/thy.2010.0021
    • B. Aschebrook-Kilfoy, M.H. Ward, M.M. Sabra, S.S. Devesa, Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 21(2), 125-134 (2011)
    • (2011) Thyroid , vol.21 , Issue.2 , pp. 125-134
    • Aschebrook-Kilfoy, B.1    Ward, M.H.2    Sabra, M.M.3    Devesa, S.S.4
  • 3
    • 65549128212 scopus 로고    scopus 로고
    • Anaplastic thyroid cancer: Molecular pathogenesis and emerging therapies
    • 18987168 10.1677/ERC-08-0154 1:CAS:528:DC%2BD1MXptlOiu7o%3D
    • R.C. Smallridge, L.A. Marlow, J.A. Copland, Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16(1), 17-44 (2009)
    • (2009) Endocr. Relat. Cancer , vol.16 , Issue.1 , pp. 17-44
    • Smallridge, R.C.1    Marlow, L.A.2    Copland, J.A.3
  • 4
    • 72749126837 scopus 로고    scopus 로고
    • New therapeutic advances in the management of progressive thyroid cancer
    • 19218279 10.1677/ERC-08-0335 1:CAS:528:DC%2BD1MXht1GnurjO
    • J.A. Woyach, M.H. Shah, New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer 16(3), 715-731 (2009)
    • (2009) Endocr. Relat. Cancer , vol.16 , Issue.3 , pp. 715-731
    • Woyach, J.A.1    Shah, M.H.2
  • 5
    • 77956519744 scopus 로고    scopus 로고
    • A phase II study of imatinib in patients with advanced anaplastic thyroid cancer
    • 20718683 10.1089/thy.2010.0057 1:CAS:528:DC%2BC3cXhtFehu7jN
    • H.T. Ha, J.S. Lee, S. Urba, R.J. Koenig, J. Sisson, T. Giordano, F.P. Worden, A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20(9), 975-980 (2010)
    • (2010) Thyroid , vol.20 , Issue.9 , pp. 975-980
    • Ha, H.T.1    Lee, J.S.2    Urba, S.3    Koenig, R.J.4    Sisson, J.5    Giordano, T.6    Worden, F.P.7
  • 7
    • 16844367677 scopus 로고    scopus 로고
    • Novel vascular targeting/disrupting agents: Combretastatin A4 phosphate and related compounds
    • 15717941 10.1007/s11912-005-0033-x 1:CAS:528:DC%2BD28XktVamsA%3D%3D
    • M.M. Cooney, J. Ortiz, R.M. Bukowski, S.C. Remick, Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr. Oncol. Rep. 7(2), 90-95 (2005)
    • (2005) Curr. Oncol. Rep. , vol.7 , Issue.2 , pp. 90-95
    • Cooney, M.M.1    Ortiz, J.2    Bukowski, R.M.3    Remick, S.C.4
  • 8
    • 77952420148 scopus 로고    scopus 로고
    • Proteasome inhibition: A new therapeutic strategy to cancer treatment
    • 20133049 10.1016/j.canlet.2009.12.002 1:CAS:528:DC%2BC3cXlsVyitr0%3D
    • W.K. Wu, C.H. Cho, C.W. Lee, K. Wu, D. Fan, J. Yu, J.J. Sung, Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett. 293(1), 15-22 (2010)
    • (2010) Cancer Lett. , vol.293 , Issue.1 , pp. 15-22
    • Wu, W.K.1    Cho, C.H.2    Lee, C.W.3    Wu, K.4    Fan, D.5    Yu, J.6    Sung, J.J.7
  • 9
    • 77953681275 scopus 로고    scopus 로고
    • Bortezomib
    • 20072838 10.1007/978-3-642-01222-8-12 1:CAS:528:DC%2BC3cXhtlKgsLbN
    • H. Einsele, Bortezomib. Recent Results Cancer Res. 184, 173-187 (2010)
    • (2010) Recent Results Cancer Res. , vol.184 , pp. 173-187
    • Einsele, H.1
  • 15
    • 79952747231 scopus 로고    scopus 로고
    • Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer
    • 10.1111/j.1349-7006.2011.01853.x
    • A. Wunderlich, M. Fischer, T. Schlosshauer, A. Ramaswamy, B.H. Greene, C. Brendel, D. Doll, D. Bartsch, S. Hoffmann, Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer Sci. 102(4), 746-756 (2011)
    • (2011) Cancer Sci. , vol.102 , Issue.4 , pp. 746-756
    • Wunderlich, A.1    Fischer, M.2    Schlosshauer, T.3    Ramaswamy, A.4    Greene, B.H.5    Brendel, C.6    Doll, D.7    Bartsch, D.8    Hoffmann, S.9
  • 16
    • 0026362229 scopus 로고
    • The molecular biology of the human anaplastic thyroid carcinoma cell
    • 1726928 1:STN:280:DyaK3s3gtVSnsw%3D%3D
    • N.E. Heldin, B. Westermark, The molecular biology of the human anaplastic thyroid carcinoma cell. Thyroidology 3, 127-131 (1991)
    • (1991) Thyroidology , vol.3 , pp. 127-131
    • Heldin, N.E.1    Westermark, B.2
  • 17
    • 0029823530 scopus 로고    scopus 로고
    • Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo
    • 10.1210/jc.81.10.3650
    • K.B. Ain, S. Tofiq, K.D. Taylor, Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J. Clin. Endocrinol. Metab. 81, 3650-3653 (1999)
    • (1999) J. Clin. Endocrinol. Metab. , vol.81 , pp. 3650-3653
    • Ain, K.B.1    Tofiq, S.2    Taylor, K.D.3
  • 18
    • 33750453810 scopus 로고    scopus 로고
    • Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors - A novel antiproliferative/antiangiogenic strategy in thyroid cancer
    • 17053904 10.1007/s00423-006-0104-y 1:STN:280:DC%2BD28njsFGqsA%3D%3D
    • S. Hoffmann, S. Gläser, A. Wunderlich, S. Lingelbach, C. Dietrich, A. Burchert, H. Müller, M. Rothmund, A. Zielke, Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors - a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch. Surg. 391(6), 589-596 (2006)
    • (2006) Langenbecks Arch. Surg. , vol.391 , Issue.6 , pp. 589-596
    • Hoffmann, S.1    Gläser, S.2    Wunderlich, A.3    Lingelbach, S.4    Dietrich, C.5    Burchert, A.6    Müller, H.7    Rothmund, M.8    Zielke, A.9
  • 19
    • 0019750732 scopus 로고
    • Criteria for analyzing interactions between biologically active agents
    • 10.1016/S0065-230X(08)60912-4
    • M.C. Berenbaum, Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res. 3, 269-335 (1981)
    • (1981) Adv. Cancer Res. , vol.3 , pp. 269-335
    • Berenbaum, M.C.1
  • 21
    • 72749126837 scopus 로고    scopus 로고
    • New therapeutic advances in the management of progressive thyroid cancer
    • 10.1677/ERC-08-0335
    • J.A. Woyach, M.H. Shah, New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer 3, 715-731 (2009)
    • (2009) Endocr. Relat. Cancer , vol.3 , pp. 715-731
    • Woyach, J.A.1    Shah, M.H.2
  • 23
    • 79251482174 scopus 로고    scopus 로고
    • AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947
    • 21071467 10.1677/ERC-10-0234 1:CAS:528:DC%2BC3MXjsFWqu7w%3D
    • S. Libertini, A. Abagnale, C. Passaro, G. Botta, S. Barbato, P. Chieffi, G. Portella, AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr. Relat. Cancer 18(1), 129-141 (2011)
    • (2011) Endocr. Relat. Cancer , vol.18 , Issue.1 , pp. 129-141
    • Libertini, S.1    Abagnale, A.2    Passaro, C.3    Botta, G.4    Barbato, S.5    Chieffi, P.6    Portella, G.7
  • 27
    • 60249101252 scopus 로고    scopus 로고
    • Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels
    • 19041685 10.1016/j.biochi.2008.10.015 1:CAS:528:DC%2BD1MXit1Kltbk%3D
    • D. Baiz, G. Pozzato, B. Dapas, R. Farra, B. Scaggiante, M. Grassi, L. Uxa, C. Giansante, C. Zennaro, G. Guarnieri, G. Grassi, Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 91(3), 373-382 (2009)
    • (2009) Biochimie , vol.91 , Issue.3 , pp. 373-382
    • Baiz, D.1    Pozzato, G.2    Dapas, B.3    Farra, R.4    Scaggiante, B.5    Grassi, M.6    Uxa, L.7    Giansante, C.8    Zennaro, C.9    Guarnieri, G.10    Grassi, G.11
  • 29
    • 70450243091 scopus 로고    scopus 로고
    • Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis
    • 10.1007/s10637-008-9206-4
    • A. Brüning, P. Burger, M. Vogel, M. Rahmeh, K. Friese, M. Lenhard, A. Burges, Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Investig. New Drugs 27(6), 543-551 (2008)
    • (2008) Investig. New Drugs , vol.27 , Issue.6 , pp. 543-551
    • Brüning, A.1    Burger, P.2    Vogel, M.3    Rahmeh, M.4    Friese, K.5    Lenhard, M.6    Burges, A.7
  • 30
    • 33748369901 scopus 로고    scopus 로고
    • Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells
    • 16928825 10.1158/1535-7163.MCT-05-0437 1:CAS:528:DC%2BD28XosVansLg%3D
    • S.E. Canfield, K. Zhu, S.A. Williams, D.J. McConkey, Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol. Cancer Ther. 5(8), 2043-2050 (2006)
    • (2006) Mol. Cancer Ther. , vol.5 , Issue.8 , pp. 2043-2050
    • Canfield, S.E.1    Zhu, K.2    Williams, S.A.3    McConkey, D.J.4
  • 31
    • 3042562304 scopus 로고    scopus 로고
    • The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts
    • 14749476 1:CAS:528:DC%2BD2cXntFaisg%3D%3D
    • S.T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, D.J. McConkey, The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 3(1), 59-70 (2004)
    • (2004) Mol. Cancer Ther. , vol.3 , Issue.1 , pp. 59-70
    • Nawrocki, S.T.1    Sweeney-Gotsch, B.2    Takamori, R.3    McConkey, D.J.4
  • 32
    • 10344236486 scopus 로고    scopus 로고
    • Aurora-kinase inhibitors as anticancer agents
    • 15573114 10.1038/nrc1502 1:CAS:528:DC%2BD2cXhtVarsLjN
    • N. Keen, S. Taylor, Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4(12), 927-936 (2004)
    • (2004) Nat. Rev. Cancer , vol.4 , Issue.12 , pp. 927-936
    • Keen, N.1    Taylor, S.2
  • 33
    • 67651146527 scopus 로고    scopus 로고
    • Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells
    • 19584233 10.1158/1535-7163.MCT-09-0323 1:CAS:528:DC%2BD1MXosVymt7g%3D
    • P. Kaestner, A. Stolz, H. Bastians, Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol. Cancer Ther. 8(7), 2046-2056 (2009)
    • (2009) Mol. Cancer Ther. , vol.8 , Issue.7 , pp. 2046-2056
    • Kaestner, P.1    Stolz, A.2    Bastians, H.3
  • 34
    • 77949770773 scopus 로고    scopus 로고
    • MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo
    • 20197380 10.1158/1541-7786.MCR-09-0300 1:CAS:528:DC%2BC3cXjt1GmsL0%3D
    • J.J. Huck, M. Zhang, A. McDonald, D. Bowman, K.M. Hoar, B. Stringer, J. Ecsedy, M.G. Manfredi, M.L. Hyer, MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol. Cancer Res. 8(3), 373-384 (2010)
    • (2010) Mol. Cancer Res. , vol.8 , Issue.3 , pp. 373-384
    • Huck, J.J.1    Zhang, M.2    McDonald, A.3    Bowman, D.4    Hoar, K.M.5    Stringer, B.6    Ecsedy, J.7    Manfredi, M.G.8    Hyer, M.L.9
  • 36
    • 34447137322 scopus 로고    scopus 로고
    • Vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. BMC Cancer. 7, 95 (2007)
    • J. Zhang, B. Peng, in vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma
    • (2007) BMC Cancer , vol.7 , pp. 95
    • Zhang, J.1    Peng, B.2
  • 38
    • 79952356422 scopus 로고    scopus 로고
    • Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression
    • 20872175 10.1007/s10456-010-9189-6 1:CAS:528:DC%2BC3cXhsVWqt7zO
    • S. Greenberger, I. Adini, E. Boscolo, J.B. Mulliken, J. Bischoff, Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 13(4), 327-335 (2010)
    • (2010) Angiogenesis , vol.13 , Issue.4 , pp. 327-335
    • Greenberger, S.1    Adini, I.2    Boscolo, E.3    Mulliken, J.B.4    Bischoff, J.5
  • 39
    • 80054040745 scopus 로고    scopus 로고
    • Effect of bortezomib on VEGF gene expression of endothelial cell line HMEC-1 and its possible mechanisms
    • 20561442 1:CAS:528:DC%2BC3cXht1yltr7P
    • L.X. Xue, M. Jiang, L.Q. Xie, C.G. Ruan, Effect of bortezomib on VEGF gene expression of endothelial cell line HMEC-1 and its possible mechanisms. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18(3), 744-748 (2010)
    • (2010) Zhongguo Shi Yan Xue Ye Xue Za Zhi. , vol.18 , Issue.3 , pp. 744-748
    • Xue, L.X.1    Jiang, M.2    Xie, L.Q.3    Ruan, C.G.4
  • 40
    • 84979846419 scopus 로고    scopus 로고
    • The effect of bortezomib on migration of endothelial cells and angiogenesis
    • 21122357 1:CAS:528:DC%2BC3cXht1SgsbbJ
    • L.X. Xue, M. Jiang, L.Q. Xie, C.G. Ruan, The effect of bortezomib on migration of endothelial cells and angiogenesis. Zhonghua Xue Ye Xue Za Zhi. 31(6), 403-406 (2010)
    • (2010) Zhonghua Xue Ye Xue Za Zhi. , vol.31 , Issue.6 , pp. 403-406
    • Xue, L.X.1    Jiang, M.2    Xie, L.Q.3    Ruan, C.G.4
  • 43
    • 34547582308 scopus 로고    scopus 로고
    • Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma
    • 17689684 10.1016/j.surg.2007.04.012
    • J.B. Hamner, P.V. Dickson, T.L. Sims, J. Zhou, Y. Spence, C.Y. Ng, A.M. Davidoff, Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 142(2), 185-191 (2007)
    • (2007) Surgery , vol.142 , Issue.2 , pp. 185-191
    • Hamner, J.B.1    Dickson, P.V.2    Sims, T.L.3    Zhou, J.4    Spence, Y.5    Ng, C.Y.6    Davidoff, A.M.7
  • 44
    • 80052782931 scopus 로고    scopus 로고
    • ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin
    • 21159048 10.1111/j.1447-0756.2010.01414.x 1:CAS:528:DC%2BC3MXovVyhsrY%3D
    • L. Zhang, S. Zhang, ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. J. Obstet. Gynaecol. Res. 37(6), 591-600 (2011)
    • (2011) J. Obstet. Gynaecol. Res. , vol.37 , Issue.6 , pp. 591-600
    • Zhang, L.1    Zhang, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.